Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Depreciation & Amortization (CF) (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $468000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 8.59% to $468000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 1.5% decrease, with the full-year FY2025 number at $2.0 million, down 1.5% from a year prior.
  • Depreciation & Amortization (CF) was $468000.0 for Q4 2025 at Janux Therapeutics, down from $501000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $541000.0 in Q2 2025 to a low of $9000.0 in Q1 2021.
  • A 5-year average of $349900.0 and a median of $469500.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 2600.0% in 2021, then fell 8.59% in 2025.
  • Janux Therapeutics' Depreciation & Amortization (CF) stood at $64000.0 in 2021, then skyrocketed by 529.69% to $403000.0 in 2022, then surged by 31.76% to $531000.0 in 2023, then dropped by 3.58% to $512000.0 in 2024, then dropped by 8.59% to $468000.0 in 2025.
  • Per Business Quant, the three most recent readings for JANX's Depreciation & Amortization (CF) are $468000.0 (Q4 2025), $501000.0 (Q3 2025), and $541000.0 (Q2 2025).